anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis-associated encephalopathy is a common neurological complication of sepsis that is characterized by neuroinflammation, oxidative stress and apoptosis, which results in cognitive impairments in septic survivors. Despite numerous treatment options for this condition, none of them are definite. Therefore, this study aimed to investigate the impact of morin, a flavone known for its neuroprotective and anti-inflammatory effects, against lipopolysaccharides-induced sepsis-associated encephalopathy in albino mice for 7 days. Mice were divided into 4 groups: Negative control, morin, septic, and septic morin-treated mice. Sepsis was induced by a single injection of lipopolysaccharides (5 mg/kg, intraperitoneally), morin (50 mg/kg b. wt.) was given orally, starting from 5 h after sepsis induction, then daily for 4 other days. Morin ameliorated septic structural and functional alternations as manifested by improving the survival rate, the behavioral functions, in addition to preserving and protecting the brain tissue. This was accompanied with the augmentation of the total antioxidant capacity, as well as the suppression of tissue levels of the lipid peroxidation marker malondialdehyde, apoptosis (cleaved-caspase-3), glial fibrillary acidic protein, and the proinflammatory cytokine tumor necrosis factor. In conclusion, morin has a promising ameliorative effect to counteract the sepsis-associated encephalopathy via its anti-inflammatory and antioxidant effects and to prevent the associated cognitive impairments.
An ingestible composition comprising a fibre or saccharide bulking agent, silica, and a surfactant, the composition being dispersable in water. Preferably, the fibre is plant-derived selected from cellulose or derivative thereof, a bran, or most preferably, ispaghula, a natural material of benefit in promoting good bowel function. The saccharide bulking agent is preferably polysaccharide-containing, more preferably an algin. Preferably, the surfactant is polyethylene-, polypropylene-, or polyoxyethylene-based. The preferred polyethylene-based surfactant is polyethylene glycol or a glycerol polyethylene glycol oxystearate. The preferred polyoxyethylene-based surfactant is a polyoxyethylene sorbitan fatty acid ester or a polyoxyethylene monostearate. Also, a method of making such an ingestible composition, the method comprising blending of the ingredients, preferably without the employment of isopropanol (or other solvent) or polyvinyl pyrrolidone (or any other granulating agent). The composition may help alleviate constipation and other digestive dysfunctions.
The invention relates to the technical field of traditional Chinese medicine compound, in particular to a gynecological external hot-compress acupoint traditional Chinese medicine composition, which comprises beefwood-like clubmoss herb, common clubmoss herb, herba asari, crinis carbonisatus, angelica, safflower, wood peel, patrinia, notopterygium root, sargentgloryvine stem, ligusticum chuanxiong hort and beefwood-like clubmoss herb: dispelling wind and removing dampness; relaxing muscles and tendons and promoting blood circulation; improving eyesight; and (5) detoxifying. The herba Hyperici perforati has effects of dispelling pathogenic wind, dredging collaterals, promoting blood circulation, clearing heat and promoting diuresis. Asarum herb has the effects of warming meridians and relieving pain, and is used for treating muscle and joint pain caused by pathogenic cold entering collaterals. Chuan Xiong is used for irregular menstruation, amenorrhea and dysmenorrhea. The effective components can penetrate into the skin by transdermal absorption, so as to solve the problem of worry and difficulty in speaking for women. Has good curative effect on pelvic inflammation, dysmenorrhea, waist soreness, lumbago, waist swelling, menoxenia, hyposexuality, etc. caused by premenstrual and postmenstrual menstruation, and has especially obvious curative effect on serious cold womb. Is prepared from multiple Chinese medicinal herbs by pulverizing into powder, bagging, and heating in a heating bag. The white spirit is added to moisten and wet the hot compress the Guanyuan acupoint, and the preparation process is simple and practical.
PURPOSE: To evaluate the efficacy of intravitreal brolucizumab in polyp regression of treatment-naive polypoidal choroidal vasculopathy (PCV) patients and its effect on 1-year treatment outcome.
METHODS: Medical records of 31 treatment-naive PCV patients, who received three monthly intravitreal brolucizumab injections followed by as-needed injections for at least a year, were retrospectively reviewed. Visual and anatomical outcomes were evaluated at 3, 6, and 12 months. Complete polyp regression rate and percentage change of vascular lesion and polyp area were evaluated after three monthly injections of brolucizumab. The effect of complete polyp regression and the impact of vascular lesion and polyp reduction rate on 1-year treatment outcome were also evaluated.
RESULTS: In terms of visual outcome, best-corrected visual acuity significantly improved after 12-month follow-up (p < 0.001). In terms of anatomical outcome, central macular thickness (CMT) and central choroidal thickness significantly decreased after 12-month follow-up (p < 0.001). Complete polyp regression was observed in 23 patients (74.2%) after three monthly injections. Group with complete polyp regression had a higher rate of achieving dry macula at 3 months (p = 0.026) and fewer number of injections (p < 0.001) compared to the group without complete polyp regression. Higher polyp reduction rate was significantly associated with higher CMT change from baseline at 3 months (p = 0.048) while higher vascular lesion reduction rate was significantly associated with higher CMT change from baseline at 12 months (p = 0.031) and fewer number of injections (p = 0.012).
CONCLUSIONS: Intravitreal brolucizumab injection effectively improved visual and anatomical outcomes and achieved significant polyp regression in treatment-naive PCV patients. Complete polyp regression and the reduction rate of vascular lesion size and polyp size after loading injection significantly influence the treatment outcome of PCV patients. However, careful monitoring and preoperative warning is warranted due to occurrence of brolucizumab-related IOI.
Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The first matching approach selected all subjects with diabetes mellitus and hypertension, and available data to match participants who received AT-001 for gender, age group (in bins of 5 years), weight, and C-reactive protein (CRP) value at the time of hospital admission.
Cases of Head and Neck Cancer identified in North West England in 2002/2003. Observational study - no intervention other than usual care.
BACKGROUND: Researchers have previously reported that mitochondrial DNA copy number (mtDNA-CN) can play different roles in microsatellite instable/mismatch repair-deficient (MSI/dMMR) and microsatellite stable/mismatch repair-proficient (MSS/pMMR) colorectal cancer (CRC). To support malignancy, dMMR CRC relies on glycolysis, while pMMR CRC favors oxidative phosphorylation. However, it is unclear whether mtDNA-CN changes are related to T cell infiltration in CRC.
METHODS: The mtDNA-CN was detected by qRT-PCR in 532 patients, and the expression of CD3 and CD8 in 485 patients was detected by immunohistochemistry. The correlation between mtDNA-CN and the prognosis of CRC patients was further analyzed, and the correlation between mtDNA-CN and T lymphocyte infiltration was also analyzed. Biopsy specimens from the immune checkpoint inhibitors (ICIs) treatment cohort were obtained to verify the correlation between mtDNA-CN and the efficacy of ICIs. The effects of mtDNA-CN and MMR status on gene expression were analyzed by RNA-seq.
RESULTS: Our results show that mtDNA-CN has inverse relationships to CRC prognosis in cases with different MMR statuses, potentially inducing the U-shaped association in CRC. The opposing correlations between mtDNA-CN and T lymphocyte infiltration in cases of dMMR CRC and pMMR CRC further suggest that mtDNA-CN might play an important role in CRC development. More importantly, cases of pMMR CRC with lower mtDNA-CN and of dMMR CRC with higher mtDNA-CN can benefit more dramatically from ICIs. Furthermore, RNA-seq revealed a link between the level of mtDNA-CN and T lymphocyte infiltration in CRC cases with different MMR statuses.
CONCLUSION: Our study found a potential relationship between mtDNA-CN and CRC development that differs by MMR status, potentially providing a rationale for the use of mtDNA-CN as both a predictive biomarker and a therapeutic target for ICIs.
The present disclosure is related to the provision of raw or cooked food products by at least one of the following cooking methods: steamed, with a pan, baked by convection or microwaved or even fried, obtained with flours supplemented with stabilized flavonoids (resists high temperatures and acidic pH) through nano-encapsulation with a biodegradable and biocompatible polymer. As an example of these food products, we can mention doughs, tamales, tortillas, bread, fried foods, and cookies, inter alia. These food products are characterized by having a hypocholesterolemic effect, obesity reduction, blood glucose modulation and antioxidants. An obtaining process of cereal flour and/or substitutes with stabilized flavonoids (stabilized (resists high temperatures and acidic pH). By means of nano-encapsulation with biocompatible and biodegradable polymers and the supplemented cereal flours and/or substitutes obtained by said process characterized in that contains stabilized and protected compounds with natural polymers. The ingredient consists of a composition of flavonoids with hypocholesterolemic, anti-hyperglycemic and antioxidant activity with biodegradable, biocompatible polymers, from hyaluronic acid, chitosan and poly (2-methacryloxybenzoic acid). Functionalized to give them characteristics of being thermostable and that resist acidic pH conditions (pH that is characteristic in the stomach). In addition, this polymer is capable of degrading and releasing flavonoids under basic pH conditions, these pH conditions are characteristic of the small intestine and colon of the human being, where said compounds are absorbed. Consequently, this ingredient favors the absorption of flavonoids due to accumulation in the colon and intestine. Keywords: Food, flavonoid, diabetes, hypercholesterolemia, antioxidant.
PURPOSE:To enable quick and simple detection of an antibody to a ciliary antigen of Bacteroides-gingivalis (B-g) by using a sensitized latex sample which is obtained by making the ciliary antigen adsorbed on a latex particle. CONSTITUTION:The title reagent is formed of latex particles prepared by making a ciliary antigen of B-g sensitize the same. The latex particle to be used for sensitization by the ciliary antigen of B-g needs only to be the one that is used ordinarily for a reagent for immunoassay. As for the ciliary antigen of B-g, the B-g is cultivated under the anaerobic condition. After the cultivation, mycelia are collected and cilia thereof are separated. In order to make this ciliary antigen of B-g sensitize the latex particle, subsequently, a physical adsorption method and a chemical combination method are adopted. A suspension of the latex particles prepared by making the ciliary antigen of B-g thus obtained sensitize the same and a subject of a man are mixed and the state of agglutination of the latex particles is observed or measured. Thereby the presence or absence of an antibody to the ciliary antigen of B-g or the quantity thereof in the subject is checked up.
Participants were to receive 375 mg/m\^2 of rituximab, administered by intravenous (I.V.) infusion every 8 weeks, starting 8 to 12 weeks after the last R-chemotherapy cycle. (Maximum duration of study was up to approximately 2.7 months).
A woman in her mid-20s, a known case of congenital afibrinogenaemia, presented with abdominal pain and distension. She was diagnosed with decompensated liver cirrhosis due to Budd-Chiari syndrome. She underwent deceased donor liver transplantation. Preoperatively, her serum fibrinogen level was undetectable and prothrombin time and international normalised ratio (INR) were unrecordable. Intraoperatively, she was given thromboelastography-guided human fibrinogen concentrate. Postoperatively, her fibrinogen, prothrombin time and INR normalised rapidly. This report summarises the rare occurrence of a complication of hypercoagulability (Budd-Chiari syndrome) in the setting of congenital hypocoagulability (congenital afibrinogenaemia). In this report, we discuss the simultaneous management of these two clinical problems and the curative role of liver transplantation.
The primary tumor ("root") and circulating tumor cells (CTCs; "seeds") are vital factors in tumor progression. However, current treatment strategies mainly focus on inhibiting the tumor while ignoring CTCs, resulting in tumor metastasis. Here, we design a multifunctional 3D scaffold with interconnected macropores, excellent photothermal ability and perfect bioaffinity as a blood vessel implantable device. When implanted upstream of the primary tumor, the scaffold intercepts CTCs fleeing back to the primary tumor and then forms "micro-thrombi" to block the supply of nutrients and oxygen to the tumor for embolization therapy. The scaffold implanted downstream of the tumor efficiently captures and photothermally kills the CTCs that escape from the tumor, thereby preventing metastasis. Experiments using rabbits demonstrated excellent biosafety of this scaffold with 86% of the CTC scavenging rate, 99% of the tumor inhibition rate and 100% of CTC killing efficiency. The multifunctional 3D scaffold synergistically inhibits the "root" and eliminates the "seeds" of the tumor, demonstrating its potential for localized cancer therapy with few side effects and high antitumor efficacy.
Infections due to Gram-positive Bacteria

A safety and efficacy study provided experience on the use of ZYVOX in pediatric patients for the treatment of nosocomial pneumonia, complicated skin and skin structure infections, and other infections due to Gram-positive bacterial pathogens, including methicillin-resistant and -susceptible Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Pediatric patients ranging in age from birth through 11 years with infections caused by the documented or suspected Gram-positive bacteria were enrolled in a randomized, open-label, comparator-controlled trial. One group of patients received ZYVOX I.V. Injection 10 mg/kg every 8 hours followed by ZYVOX for Oral Suspension 10 mg/kg every 8 hours. A second group received vancomycin 10 to 15 mg/kg intravenously every 6 to 24 hours, depending on age and renal clearance. Patients who had confirmed VRE infections were placed in a third arm of the study and received ZYVOX 10 mg/kg every 8 hours intravenously and/or orally. All patients were treated for a total of 10 to 28 days and could receive concomitant Gram-negative antibacterial drugs if clinically indicated. In the intent-to-treat (ITT) population, there were 206 patients randomized to linezolid and 102 patients randomized to vancomycin. The cure rates for ITT, MITT, and clinically evaluable patients are presented in Table 16. After the study was completed, 13 additional patients ranging from 4 days through 16 years of age were enrolled in an open-label extension of the VRE arm of the study. Table 17 provides clinical cure rates by pathogen for microbiologically evaluable patients including microbiologically evaluable patients with vancomycin-resistant Enterococcus faecium from the extension of this study.
INTRODUCTION: Nurses' preparedness to provide hemorrhage control aid outside of the patient care setting has not been thoroughly evaluated. We evaluated nurses' preparedness to provide hemorrhage control in the prehospital setting after a proof-of-concept training event.
METHODS: We performed a secondary analysis of evaluations from a voluntary hemorrhage control training offered to a group of experienced nurses. Education was provided by a nurse certified in Stop the Bleed training and using the Basic Bleeding Control 2.0 materials. The training lasted approximately 1 hour and included a didactic portion followed by hands-on practice with task trainer legs. Participants were surveyed after training to assess their preparedness to provide hemorrhage control aid using a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree); comments and feedback were also requested. Mean (SD) was used to analyze Likert scale data. Content analysis was performed to identify common themes in qualitative data.
RESULTS: Forty-five experienced nurses participated in the voluntary training. Nursing experience included obstetrics, pediatrics, critical care, acute care, community health, and psychiatric/mental health. Only 39% of participants reported having previously completed a similar course. After training completion, participants reported an increase in their preparedness to provide hemorrhage control aid (mean 3.47 [SD = 1.40] vs mean 4.8 SD [.04], P < .01). Major themes identified included wanting to feel prepared to help others, refreshing skills, and knowing how to respond in an emergency.
DISCUSSION: Regardless of background and experience, nurses may benefit from more advanced hemorrhage control education to prepare them to provide aid in prehospital emergency settings.
Participants randomized to Condition 3 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The "survival following transplant" metric is displayed as a quintile score corresponding to all patients at the center who received transplants.
The invention provides a method of treating any condition of elevated levels of unconjugated bilirubin in adults or children, such as Gilbert's syndrome or liver cirrhosis. The method calls for the administration of chrysin or chrysin analogs via dietary or other means. Also provided is a method of increasing glucuronidation of bilirubin in a subject, comprising administering to the subject an amount of chrysin effective to increase the glucuronidation of bilirubin. A method of increasing the expression of UDP-glucuronosyltransferase in a subject is provided, comprising administering to the subject an amount of chrysin effective to increase the UDP-glucuronosyltransferase. Upregulation of the expression of UDP-glucuronosyltransferase levels is expected to be beneficial in a number of areas: 1) increased detoxification of ingested carcinogens, such as the cooked-food mutagens (chrysin is an aromatase inhibitor in cells); 2) decreasing the conversion of androgens to estrogens, potentially building muscle mass or for prevention of breast cancer in women. In the method of upregulating UGT, UDP-glucuronosyltransferase can be a UGT1A isoform. A method of treating colon cancer is provided, comprising administering an effective amount of a flavone, whereby the administration of the flavone treats the colon cancer.
Micro organisms are useful in management of diseases including diarrhoea and gastro intestinal diseases like pseudomembranous colitis, megacolon etc. They are also useful in prevention of gastro intestinal disturbances and diseases caused by anti-infective agents like ampicillin, amoxycillin, cloxacillin, clauvanic acid, cefuroxime axetel, cephalixin, erythromycin etc. For prevention micro organisms are to be taken along with anti infective agents.  When micro organisms are combined with anti-infective agents for ease of administration and improving compliance and therapeutic effect, the combination is not found to be stable at room temperature as micro organisms are sensitive to anti-infective agents and are destroyed by effect of anti-infective agent in composition. The present invention relates to the process of preparing a stable fixed dose composition of anti-infective agent with micro organism as active ingredient. The process includes preparation of various dosage forms for oral route like capsule, tablet and liquid formulation. The process comprises of providing an appropriate barrier by way of selected coating procedure to one of the active ingredients in such a way that micro organisms are not affected by anti-infective agents. This results in a stable composition. By using an appropriate coating technique composition is made to remain stable over a period of 3-36 months at ambient/room temperature. The ratio of micro organism to anti-infective agents in a composition can be 1:2 to 1:25 by weight. The ratio of 1:5 by weight is found to be optimal for the purpose. The amount of coating is dependent on the type of coating technique, dosage form i.e. capsule, tablet or liquid and desired self life. The micro organisms of the composition were found to be active after variable time period. They also provided therapeutic effect and eliminated gastro intestinal disturbances associated with anti-infective agents when evaluated in humans.
PURPOSE: A tertiary lymphoid structure (TLS) refers to an organized infiltration of immune cells that is linked to a positive prognosis and improved response to immunotherapy. However, methods that promote TLS formation are limited and challenging to implement in clinical settings. In this study, we aimed to promote the formation and maturation of TLSs in lung adenocarcinoma (LUAD) by combining low-dose radiotherapy (LDRT) with immunotherapy.
METHODS: Tissue sections from 198 patients who had undergone surgery were examined. Risk factors for patient survival were assessed, and the relationship between TLSs and five-year survival was analyzed. The Kras-LSL-G12D spontaneous lung cancer mouse model was used to screen the optimal irradiation dose (0/1/2 Gy whole lung irradiation) for promoting TLS formation. LDRT combined with anti-PD-1 was used to promote the formation and maturation of TLSs.
RESULTS: TLS+, TLSHigh, TLS+GC+ and CD8High within TLS+ were associated with a favorable prognosis. LDRT increased the formation of early TLSs in the Kras-LSL-G12D lung cancer mouse model. In addition, LDRT combined with anti-PD-1 treatment can significantly improve the maturity of TLSs in mouse LUAD, resulting in greater antitumor effects. This antitumor effect was strongly associated with the number of CD8+ T cells within the TLSs.
CONCLUSION: We successfully applied LDRT combined with PD-1 inhibitor therapy for the first time, which increased both the quantity and maturity of TLSs in lung cancer. This approach achieved a promising antitumor effect.
The invention relates to a method of producing a recombinant adeno-associated virus (rAAV). According to the inventive method, a helper construct and a vector construct are introduced into a suitable cell at different times. The helper construct contains no nucleic acid sequences, especially except for the AAV promoters, to which at least one rep protein can substantially specifically bind. The vector construct preferably contains ITR sequences in flop orientation. The recombinant adeno-associated viruses produced according to the inventive method are especially useful for producing a tumor cell into which additionally nucleic acids encoding GM-CSF and B7.2 were introduced. Said tumor cell can in turn be used in the form of a medicament for the treatment of cancer.
Patients with intraoperatively determined advanced unresectable PHC will be treated with IRE during the same surgical exploration session (N=20). Electrodes will be placed using ultrasound guidance. All electrodes will be placed by hepatopancreatobiliary surgeons with experience using IRE.